Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,412,767 | $1,228,834 | $1,039,346 | $807,149 |
| - Cash | $183,581 | $107,954 | $122,715 | $122,470 |
| + Debt | $9,855 | $12,258 | $5,919 | $6,050 |
| Enterprise Value | $1,239,041 | $1,133,138 | $922,550 | $690,729 |
| Revenue | $423,239 | $270,259 | $220,180 | $38,544 |
| % Growth | 56.6% | 22.7% | 471.2% | – |
| Gross Profit | $362,329 | $213,735 | $197,285 | $29,444 |
| % Margin | 85.6% | 79.1% | 89.6% | 76.4% |
| EBITDA | -$43,921 | -$22,855 | $12,175 | -$154,281 |
| % Margin | -10.4% | -8.5% | 5.5% | -400.3% |
| Net Income | -$43,193 | $14,084 | $183,363 | -$157,924 |
| % Margin | -10.2% | 5.2% | 83.3% | -409.7% |
| EPS Diluted | -0.6 | 0.2 | 2.6 | -2.3 |
| % Growth | -400% | -92.3% | 213% | – |
| Operating Cash Flow | $25,689 | $13,301 | $5,807 | -$126,298 |
| Capital Expenditures | -$277 | -$130 | -$105 | -$20,415 |
| Free Cash Flow | $25,412 | $13,171 | $5,702 | -$146,713 |